McLaurin E Y, Holliday S L, Williams P, Brey R L
National Center for Research Resources General Clinical Research Center Program, USA.
Neurology. 2005 Jan 25;64(2):297-303. doi: 10.1212/01.WNL.0000149640.78684.EA.
To evaluate predictors of cognitive dysfunction in patients with systemic lupus erythematosus (SLE).
The authors evaluated 123 patients enrolled in the San Antonio Lupus Study of Neuropsychiatric Disease (SALUD) who had completed at least 3 years of follow-up. Study visits occurred every 4 months and included a standard medical history, physical examination, and cognitive testing. Blood was obtained at each study visit for autoantibody testing.
There were 116 (94.3%) women and 7 (5.7%) men (mean age = 41.5 [+/-12.0] years). Patients had the following vascular risk factors: hypercholesterolemia (17.1%), diabetes (21.1%), and hypertension (48.0%). Consistent medication use included aspirin (21.1%), prednisone (65.0%), nonsteroidal anti-inflammatories (42.3%), and hydroxychloroquine (58.5%). The numbers of patients with consistently positive autoantibody levels were as follows: antiphospholipid, 54%; anti-beta-2-glycoprotein 1, 73%; and anti-ribosomal P, 17%. Factors significantly associated with declining cognitive function were consistently positive antiphospholipid antibodies, consistent prednisone use, diabetes, higher depression scores, and less education. The association of prednisone and poorer cognitive function was seen primarily in the middle age group and could not be totally explained by SLE-associated disease activity. Consistent aspirin use was associated with improved cognitive function, primarily in the oldest age group, especially if diabetes was also present.
Regular aspirin use is associated with improved cognitive function in older patients with systemic lupus erythematosus (SLE) in conjunction with the presence of other vascular risk factors. Regular prednisone use is associated with decreased cognitive functioning in middle-aged patients with SLE. Although this prednisone effect was independent of measures of SLE-associated disease activity, the authors cannot exclude the possibility that consistent prednisone use is a surrogate for more severe disease.
评估系统性红斑狼疮(SLE)患者认知功能障碍的预测因素。
作者评估了123名纳入圣安东尼奥狼疮神经精神疾病研究(SALUD)且完成至少3年随访的患者。每4个月进行一次研究访视,包括标准病史、体格检查和认知测试。每次研究访视时采集血液进行自身抗体检测。
有116名(94.3%)女性和7名(5.7%)男性(平均年龄 = 41.5 [±12.0]岁)。患者具有以下血管危险因素:高胆固醇血症(17.1%)、糖尿病(21.1%)和高血压(48.0%)。持续使用的药物包括阿司匹林(21.1%)、泼尼松(65.0%)、非甾体抗炎药(42.3%)和羟氯喹(58.5%)。自身抗体水平持续呈阳性的患者数量如下:抗磷脂抗体,54%;抗β2糖蛋白1,73%;抗核糖体P,17%。与认知功能下降显著相关的因素包括抗磷脂抗体持续呈阳性、持续使用泼尼松、糖尿病、抑郁评分较高以及受教育程度较低。泼尼松与较差认知功能之间的关联主要见于中年组,且不能完全由SLE相关疾病活动来解释。持续使用阿司匹林与认知功能改善相关,主要见于年龄最大的组,尤其是同时患有糖尿病时。
在患有系统性红斑狼疮(SLE)且存在其他血管危险因素的老年患者中,规律使用阿司匹林与认知功能改善相关。在中年SLE患者中,规律使用泼尼松与认知功能下降相关。尽管这种泼尼松效应独立于SLE相关疾病活动的测量指标,但作者不能排除持续使用泼尼松是更严重疾病替代指标的可能性。